AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment: Boston Saturday, November 16, 2024, 16:00 Hrs [IST] icometrix, a g ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Doctors are most concerned about the new US Health Secretary's unwarranted criticisms of vaccine safety - here his other ...

HMTM previously failed a phase 3 trial reported in 2016, and it remains to be seen whether the FDA will ... its approval of Biogen/Eisai's pathfinder amyloid drug Aduhelm (aducanumab) on mixed ...

For Biogen, an expensive gamble has paid off, as even with accelerated approval the company stands to make billions of dollars from aducanumab, given it estimates there are around 1.5 million ...

An update to our reporting on two recently-approved Alzheimer’s drugs: aducanumab and Lecanemab. FDA advisers and many independent watchdogs said there's no good evidence the hugely expensive shots ...

In the past few years, multiple treatments have been approved that target the disease in its early stages. In 2021, aducanumab was the first FDA-approved therapy that targeted the biology but is ...